Royalty Pharma plc (RPRX) AI Stock Analysis

Royalty Pharma plc operates in the biopharmaceutical industry by acquiring biopharmaceutical royalties and funding industry innovations across the United States. The company evaluates and acquires royalties associated with biopharmaceutical therapies, working in collaboration with academic institutions, research hospitals, not-for-profits, and biotechnology and pharmaceutical companies. Its portfolio features royalties on approximately 35 marketed therapies and 10 developmental-stage product candidates across areas including rare diseases, oncology, neurology, infectious diseases, hematology, and diabetes. Founded in 1996 and based in New York, New York, the company acts as a specialized financial partner supporting biopharmaceutical research and development.

Royalty Pharma recorded a 5-year revenue CAGR of 2.3% from FY2020 to FY2025. Annual revenue grew 5.1% in FY2025 to $2.38B, following a 3.9% decline in FY2024 to $2.26B and a 5.2% increase in FY2023 to $2.35B. Gross margin remained at 100.0% across all years from FY2021 through FY2025. Operating margin was 65.6% in FY2025, recovering from 57.1% in FY2024, while net income reached $770.9M. For the trailing twelve months ended June 30, 2026, revenue stood at $2.54B with a profit margin of 32.0%. In the latest quarter, quarterly revenue grew 16.5% year-over-year, while quarterly earnings fell 46.3%.

As of June 30, 2026, Royalty Pharma held $837.0M in cash and short-term investments alongside total debt of $8.96B, resulting in net debt of $8.12B. The company reported shareholders' equity of $6.83B, a debt-to-equity ratio of 1.31, and a current ratio of 1.29 against total assets of $19.82B. In FY2025, operating cash flow and free cash flow both reached $2.49B. Capital allocation in FY2025 included $1.23B spent on share buybacks and $378.3M paid in dividends, contributing to an 8.3% reduction in share count over 5 years.

Royalty Pharma trades at a trailing P/E of 32.4x and a forward P/E of 29.4x, higher than the median of its US-listed Healthcare peers at 24.6x and 17.3x, respectively. Its enterprise value stands at $32.91B with an EV to EBITDA ratio of 19.2x, compared to the peer median of 12.0x. The price-to-sales multiple is 13.9x versus the peer median of 4.1x. Over the past year, the stock returned 71.0%, outpacing the S&P 500 return of 16.8%, while its 5-year return of 78.5% trailed the S&P 500 return of 83.0%.

Royalty Pharma provides an annual forward dividend of $0.94 per share, translating to a dividend yield of 1.54%. The company has paid dividends for 7 consecutive years with a 5-year annualized dividend growth rate of 24.0%. Supported by a payout ratio of 17.6%, quarterly dividend payments totaled $378.3M in FY2025, with the last ex-dividend date occurring on August 14, 2026.

Wall Street sentiment includes 5 Strong Buy, 2 Buy, and 1 Hold ratings, with no Sell or Strong Sell recommendations. The mean price target of $65.38 represents a 7.2% premium over the last close of $60.96. For the fiscal year ending December 31, 2026, analysts estimate revenue of $3.50B and EPS of $5.32, implying 10.2% EPS growth. Royalty Pharma beat EPS estimates in each of the last 4 quarters, with its next earnings date scheduled for November 4, 2026.

This page is an AI-written research summary of Royalty Pharma plc (RPRX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: RPRX income statement, RPRX balance sheet, RPRX key metrics, RPRX analyst forecast, RPRX chart. See the RPRX stock overview for the latest quote and news.